Rifampin Exposure in Pregnant and Nonpregnant Women With Tuberculosis in India
Prakruti Rao, Senbagavalli Prakash Babu, Komala Ezhumalai, Selby Knudsen, Jayalakshmy Ramakrishnan, Noyal Mariya Joseph, Chelsie Cintron, Madolyn Dauphinais, et al. (17 authors)
The Journal of Infectious Diseases · 2025-09
Abstract
This prospective cohort study evaluated rifampin pharmacokinetics in pregnant and nonpregnant women with tuberculosis in India. Pregnant women had significantly lower drug exposure, with <20% of the participants achieving target concentrations at any trimester. Findings highlight potential underdosing in pregnancy and underscore the need for dedicated pharmacokinetics studies in pregnancy, and revised rifampin dosing guidelines.
MeSH terms
- Medicine
- Tuberculosis
- Pharmacokinetics
- Pregnancy
- Dosing
- Prospective cohort study
- Rifampicin
- Cohort study
- Cohort
- Drug
- Obstetrics
- Human immunodeficiency virus (HIV)
- Gestation
- Antibiotics